Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.610
+0.290 (12.50%)
At close: Aug 13, 2025, 4:00 PM
2.660
+0.050 (1.92%)
Pre-market: Aug 14, 2025, 9:15 AM EDT
Nuvation Bio Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Nuvation Bio stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $8.00 forecasts a 206.51% increase in the stock price over the next year.
Price Target: $8.00 (+206.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $6 → $7 | Buy | Maintains | $6 → $7 | +168.20% | Aug 8, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $6 | Buy | Reiterates | $6 | +129.89% | Jun 25, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +129.89% | Jun 17, 2025 |
| Wedbush | Wedbush | Buy Maintains $5 | Buy | Maintains | $5 | +91.57% | Jun 11, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $6 | Buy | Reiterates | $6 | +129.89% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
15.65M
from 7.87M
Increased by 98.78%
Revenue Next Year
92.29M
from 15.65M
Increased by 489.71%
EPS This Year
-0.68
from -2.11
EPS Next Year
-0.64
from -0.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 23.1M | 169.7M | 270.7M | |
| Avg | 15.7M | 92.3M | 152.9M | |
| Low | 8.3M | 24.5M | 49.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 193.4% | 984.1% | 193.3% | |
| Avg | 98.8% | 489.7% | 65.7% | |
| Low | 5.2% | 56.5% | -46.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.61 | -0.38 | -0.43 | ||
| Avg | -0.68 | -0.64 | -0.58 | ||
| Low | -0.70 | -0.77 | -0.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.